Elopag 50 mg Tablet

Generic Name: Eltrombopag
Brand: Everest
Strength: 50 mg
Pack Size: 14 Tablets
Manufacturer: Everest Pharmaceuticals
Distributed by: NP Molecule

Indications:

Elopag 50 mg is indicated for the treatment of:

• Chronic Immune Thrombocytopenia (ITP) in adult and pediatric patients who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

• Thrombocytopenia in patients with chronic Hepatitis C to allow initiation and maintenance of interferon-based therapy.

• Severe Aplastic Anemia (SAA) in patients who are refractory to other treatments.

Pharmacology:

Eltrombopag is a thrombopoietin receptor agonist. It binds to and activates the thrombopoietin receptor (TPO-R), leading to the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells. This ultimately increases platelet production.

Dosage & Administration:

• The starting dose and regimen should be based on the specific condition being treated, age, liver function, and platelet count.

• Tablets should be taken on an empty stomach, at least 1 hour before or 2 hours after eating, particularly avoiding dairy and calcium-rich foods which may interfere with absorption.

Interaction:

• Eltrombopag can interact with polyvalent cation-containing products (antacids, supplements with calcium, magnesium, aluminum).

• Close monitoring is needed when used with hepatotoxic drugs or in patients with liver disorders.

Contraindications:

• Hypersensitivity to Eltrombopag or any component of the formulation.

Side Effects:

Common side effects include:

• Nausea, headache, fatigue, diarrhea

• Increased liver enzymes

• Risk of thrombotic/thromboembolic complications

Pregnancy & Lactation:

• Use during pregnancy should be considered only if clearly needed.

• It is unknown whether Eltrombopag is excreted in human milk; caution is advised for lactating mothers.

Precautions & Warnings:

• Monitor liver function tests regularly.

• Risk of hepatotoxicity and thrombotic events.

• Use with caution in patients with liver impairment.

• Regular monitoring of platelet counts is essential to avoid excessive thrombocytosis.

Overdose Effects:

• May lead to excessive platelet counts and risk of thrombotic complications.

• In case of overdose, discontinue medication and provide supportive treatment.

Therapeutic Class:

• Hematopoietic Agents

• Thrombopoietin Receptor Agonists

Storage Conditions:

• Store below 30°C in a dry place.

• Protect from light and moisture.

• Keep out of reach of children.